Contact
Please use this form to send email to PR contact of this press release:
Preclinical Study on Enhancing Sacituzumab Govitecan (IMMU-132) Activity in SN-38-Resistant Cancer Cells Published
TO:
Please use this form to send email to PR contact of this press release:
Preclinical Study on Enhancing Sacituzumab Govitecan (IMMU-132) Activity in SN-38-Resistant Cancer Cells Published
TO: